Related Experiment Video

Updated: Jun 20, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Insulin intensification--the rationale and the target

A Liebl1

  • 1Department for Internal Medicine, Center for Diabetes and Metabolism, m&i-Fachklinik, Woernerweg 30, Bad Heilbrunn, Germany. Andreas.Liebl@fachklinik-bad-heilbrunn.de

International Journal of Clinical Practice. Supplement
|September 16, 2009
PubMed
Abstract

Insights

Achieving early glycaemic control in type 2 diabetes is crucial for reducing long-term risks by mitigating the metabolic memory effect. Individualized treatment plans are essential for effective diabetes management.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Primary Care Medicine

Background:

  • Type 2 diabetes management requires effective glycaemic control to prevent long-term complications.
  • The concept of 'metabolic memory' suggests early hyperglycaemia influences future risk.
  • Primary care plays a vital role in implementing diabetes management strategies.

Purpose of the Study:

  • To review evidence on glycaemic control targets in type 2 diabetes.
  • To assess the implications of these targets for primary care management.
  • To understand the role of early intervention in diabetes care.

Main Methods:

  • Comprehensive literature review of key evidence.
  • Analysis of studies on intensive glycaemic control.
  • Examination of current management guidelines.

Main Results:

  • Early glycaemic control may reduce long-term risks by minimizing the metabolic memory effect.
  • Intensive treatment studies have not consistently confirmed expected risk reductions, possibly due to delayed control.
  • Guidelines emphasize glycaemic targets but vary in dose intensification strategies, stressing individualization.

Conclusions:

  • Early achievement of glycaemic control targets is important for reducing long-term diabetes-related risks.
  • Treatment strategies for type 2 diabetes must be individualized to meet patient needs.
  • Primary care providers should focus on timely and tailored glycaemic management.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat11:12

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Published on: February 7, 2011

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...